S&P 500

5.909,03

-1,11%

Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
vTv Therapeutics Inc (VTVT)
vTv Therapeutics Inc (VTVT) Notícias

VTVT

vTv Therapeutics (VTVT)

vTv Therapeutics Inc

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NASDAQ:VTVT

1 2 3 4 5 6 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
09/12/2024	09:33	PR Newswire (US)	CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER	NASDAQ:VTVT	vTv Therapeutics Inc
06/12/2024	18:15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VTVT	vTv Therapeutics Inc
12/11/2024	18:43	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:VTVT	vTv Therapeutics Inc
12/11/2024	18:26	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VTVT	vTv Therapeutics Inc
23/09/2024	17:28	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:VTVT	vTv Therapeutics Inc
28/05/2024	09:00	PR Newswire (US)	CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING	NASDAQ:VTVT	vTv Therapeutics Inc
09/05/2024	17:51	GlobeNewswire Inc.	vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update	NASDAQ:VTVT	vTv Therapeutics Inc
19/03/2024	09:30	PR Newswire (US)	CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT	NASDAQ:VTVT	vTv Therapeutics Inc
13/03/2024	09:00	GlobeNewswire Inc.	vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update	NASDAQ:VTVT	vTv Therapeutics Inc
07/03/2024	18:47	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:VTVT	vTv Therapeutics Inc
07/03/2024	16:34	Edgar (US Regulatory)	Form D - Notice of Exempt Offering of Securities	NASDAQ:VTVT	vTv Therapeutics Inc
05/03/2024	21:52	Edgar (US Regulatory)	Form SC 13D - General statement of acquisition of beneficial ownership	NASDAQ:VTVT	vTv Therapeutics Inc
04/03/2024	10:00	GlobeNewswire Inc.	vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes	NASDAQ:VTVT	vTv Therapeutics Inc
01/03/2024	10:00	GlobeNewswire Inc.	vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference	NASDAQ:VTVT	vTv Therapeutics Inc
28/02/2024	11:14	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:VTVT	vTv Therapeutics Inc
28/02/2024	10:00	GlobeNewswire Inc.	vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund	NASDAQ:VTVT	vTv Therapeutics Inc
22/02/2024	18:00	PR Newswire (US)	CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCE	NASDAQ:VTVT	vTv Therapeutics Inc
09/11/2023	18:30	GlobeNewswire Inc.	vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update	NASDAQ:VTVT	vTv Therapeutics Inc
08/11/2023	10:00	GlobeNewswire Inc.	vTv Therapeutics to Participate at the Stifel 2023 Healthcare Conference	NASDAQ:VTVT	vTv Therapeutics Inc
02/11/2023	09:00	GlobeNewswire Inc.	vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer	NASDAQ:VTVT	vTv Therapeutics Inc
01/11/2023	09:00	GlobeNewswire Inc.	vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million	NASDAQ:VTVT	vTv Therapeutics Inc
27/09/2023	09:30	PR Newswire (US)	CANTEX AND MICHIGAN MEDICINE ANNOUNCE INITIATION OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 PIVOTAL CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AZELIRAGON IN THE TREATMENT OF PATIENTS HOSPITALIZED FOR COVID-19	NASDAQ:VTVT	vTv Therapeutics Inc
26/09/2023	09:30	PR Newswire (US)	Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer	NASDAQ:VTVT	vTv Therapeutics Inc
25/09/2023	17:20	Edgar (US Regulatory)	Form DEF 14C - Other definitive information statements	NASDAQ:VTVT	vTv Therapeutics Inc
18/09/2023	09:30	PR Newswire (US)	CANTEX PHARMACEUTICALS AND LENOX HILL HOSPITAL ANNOUNCE INITIATION OF A PHASE 2 STUDY OF RAGE INHIBITOR AZELIRAGON AS A FRONT-LINE TREATMENT FOR UNMETHYLATED GLIOBLASTOMA	NASDAQ:VTVT	vTv Therapeutics Inc
15/09/2023	17:17	Edgar (US Regulatory)	Form PRE 14C - Other preliminary information statements	NASDAQ:VTVT	vTv Therapeutics Inc
11/08/2023	17:30	GlobeNewswire Inc.	vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Update	NASDAQ:VTVT	vTv Therapeutics Inc
10/08/2023	09:33	PR Newswire (US)	Cantex Pharmaceuticals Announces Article Published in npj Breast Cancer Highlighting Potential Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast Cancer	NASDAQ:VTVT	vTv Therapeutics Inc
26/06/2023	17:25	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:VTVT	vTv Therapeutics Inc
21/06/2023	17:20	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:VTVT	vTv Therapeutics Inc